Memo Therapeutics AG
We were commissioned by Memo Therapeutics AG, a late-stage biotech company, to create a distinctive new brand identity and build a new website that would enhance their visibility. Our design focused on appealing to a diverse audience, including industry professionals, with a unique logo and a bold, distinctive colour scheme.
Memo Therapeutics AG is a late-stage biotech company that are developing best-in-class therapeutic antibodies based on natural immunity in elite responders to transform the lives of patients with viral infections and cancer. They are translating unique human immune responses into superior medicines. Their lead programme, Potravitug, currently in Phase II development, is the most potent antibody ever tested in clinical trials to treat BK virus infection in kidney transplant recipients.
Memo Therapeutics AG approached TIG with a goal of creating a strong and cohesive brand identity that would encapsulate their vision, mission, and core values. Here at TIG we re-built their outdated website, which suffered from poor functionality. We also did full development of the website, making sure it was functional, user-friendly, and optimised for a seamless experience across devices. This included a fully responsive design, easy navigation, and clear calls to action for visitors.
We delivered the new site designed to enhance visibility and reach through:
- SEO optimisation
- improved UX
- faster load times
Alongside the website, TIG also developed a comprehensive rebrand, including PowerPoint video animations and infographics integrated throughout the site.
